| Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) (NCT05217667) | Arrowhead Pharmaceuticals | 2022-04-22 |
| Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia (NCT04233918) | Regeneron Pharmaceuticals | 2020-06-29 |
| Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH (NCT04034485) | LIB Therapeutics LLC | 2019-12-07 |
| A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia (NCT04031742) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-09-29 |
| A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH (NCT03933293) | Akeso | 2019-05-13 |
| A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (NCT03851705) | Novartis Pharmaceuticals | 2019-02-06 |
| Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) (NCT03455777) | Akcea Therapeutics | 2018-04-12 |
| Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia (NCT03409744) | Regeneron Pharmaceuticals | 2018-03-13 |
| HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia (NCT03135184) | HDL Therapeutics | 2018-01-26 |
| Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia (NCT03399786) | Regeneron Pharmaceuticals | 2018-01-18 |
| Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (NCT03156621) | Regeneron Pharmaceuticals | 2017-10-03 |
| HoFH, the International Clinical Collaborators Registry (NCT04815005) | University of Pennsylvania | 2017-01-24 |
| A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (NCT02963311) | The Medicines Company | 2016-12-13 |
| Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy (NCT02765841) | Aegerion Pharmaceuticals, Inc. | 2016-05-01 |
| Effects of Lomitapide on Carotid and Aortic Atherosclerosis (NCT02399852) | Aegerion Pharmaceuticals, Inc. | 2015-06-01 |
| Study to Evaluate the Effects of MBX-8025 in Patients With HoFH (NCT02472535) | Gilead Sciences | 2015-04-01 |
| Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (NCT02265952) | Regeneron Pharmaceuticals | 2015-02-04 |
| LOWER: Lomitapide Observational Worldwide Evaluation Registry (NCT02135705) | Amryt Pharma | 2014-03-18 |
| Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) (NCT01841684) | Merck Sharp & Dohme LLC | 2013-06-01 |
| Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia (NCT02286596) | Laval University | 2013-04-01 |
| Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities (NCT01588496) | Amgen | 2012-04-05 |
| Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (NCT01412034) | Cerenis Therapeutics, SA | 2011-11-01 |
| The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository (NCT01109368) | The Rogosin Institute | 2010-06-01 |
| A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) (NCT00730236) | Aegerion Pharmaceuticals, Inc. | 2007-12-01 |
| Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED) (NCT00704535) | Organon and Co | 2006-03-01 |
| Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor (NCT01556906) | Aegerion Pharmaceuticals, Inc. | 2003-06-01 |
| Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia (NCT01878604) | Central South University | 2001-10-01 |